Krsnaa Diagnostics Limited

Rs. 140

ance Krsnaa Diagnostics Financial- At a Glance Krsnaa Diagnostics Q1 FY24 Financial- At a Glance Rs. 140 cr Q1 FY24 Revenue Rs. 35 cr | 25% Q1 FY24 Normalized EBITDA* and Normalized EBITDA Margin Rs. 2

Rs. 35

ncial- At a Glance Krsnaa Diagnostics Q1 FY24 Financial- At a Glance Rs. 140 cr Q1 FY24 Revenue Rs. 35 cr | 25% Q1 FY24 Normalized EBITDA* and Normalized EBITDA Margin Rs. 23 cr | 16% Q1 FY24 Normalize

25%

Glance Krsnaa Diagnostics Q1 FY24 Financial- At a Glance Rs. 140 cr Q1 FY24 Revenue Rs. 35 cr | 25% Q1 FY24 Normalized EBITDA* and Normalized EBITDA Margin Rs. 23 cr | 16% Q1 FY24 Normalized EBIT**

Rs. 23

140 cr Q1 FY24 Revenue Rs. 35 cr | 25% Q1 FY24 Normalized EBITDA* and Normalized EBITDA Margin Rs. 23 cr | 16% Q1 FY24 Normalized EBIT** and Normalized EBIT Margin Rs. 17 cr | 12% Q1 FY24 Normalized

16%

FY24 Revenue Rs. 35 cr | 25% Q1 FY24 Normalized EBITDA* and Normalized EBITDA Margin Rs. 23 cr | 16% Q1 FY24 Normalized EBIT** and Normalized EBIT Margin Rs. 17 cr | 12% Q1 FY24 Normalized PAT** an

Rs. 17

d Normalized EBITDA Margin Rs. 23 cr | 16% Q1 FY24 Normalized EBIT** and Normalized EBIT Margin Rs. 17 cr | 12% Q1 FY24 Normalized PAT** and Normalized PAT Margin 19% Normalized PAT** YoY Growth 1

12%

d EBITDA Margin Rs. 23 cr | 16% Q1 FY24 Normalized EBIT** and Normalized EBIT Margin Rs. 17 cr | 12% Q1 FY24 Normalized PAT** and Normalized PAT Margin 19% Normalized PAT** YoY Growth 100% Tech

19%

and Normalized EBIT Margin Rs. 17 cr | 12% Q1 FY24 Normalized PAT** and Normalized PAT Margin 19% Normalized PAT** YoY Growth 100% Technical Bid Win Ratio 24% Revenue YoY Growth A (Stable)

100%

cr | 12% Q1 FY24 Normalized PAT** and Normalized PAT Margin 19% Normalized PAT** YoY Growth 100% Technical Bid Win Ratio 24% Revenue YoY Growth A (Stable) ICRA Rating 22% Normalized EBITDA*

24%

AT** and Normalized PAT Margin 19% Normalized PAT** YoY Growth 100% Technical Bid Win Ratio 24% Revenue YoY Growth A (Stable) ICRA Rating 22% Normalized EBITDA* YoY Growth Rs. 225 cr Cash

22%

PAT** YoY Growth 100% Technical Bid Win Ratio 24% Revenue YoY Growth A (Stable) ICRA Rating 22% Normalized EBITDA* YoY Growth Rs. 225 cr Cash and Cash Equivalent 79 Receivable Days 30th Jun

Rs. 225

Win Ratio 24% Revenue YoY Growth A (Stable) ICRA Rating 22% Normalized EBITDA* YoY Growth Rs. 225 cr Cash and Cash Equivalent 79 Receivable Days 30th June 2023 (Q1FY23: 86 days) Test Prices L

“In line with this judgement, the Authorities are also willing to go ahead with the Agreement and execute the project and no contest remains between the parties.”

“We anticipate a positive trajectory in margins as these centres mature over the upcoming quarters.”

“• The Indian Diagnostic Industry has displayed 1,360 substantial growth, witnessing a CAGR of 14% Paid out of Pocket 12% Source – Industry 472 377 240 684 710 596 FY12 FY15 FY17 FY18 FY20 FY21 INR Billion FY26E Source – Industry • Notably, the industry's value escalated from Rs.”

“Maturity is on the basis of the project start date 3.”

“29 Krsnaa Diagnostics Edge Krsnaa Diagnostics Edge One of the Fastest Growing Diagnostics Service Provider in the country Extensive Geographic Footprint Strong Brand Equity Scalable and Agile Business Model Disruptive Pricing Stakeholder Value Creation ₹ Total Centre count increased at a CAGR of 33% from 682 in FY18 to 2,800+ in FY23 Centres across India with presence in 17 States and Union Territories.”

Notes

4

Healthcare Services Distribution

1

Indian Diagnostic Industry Growth

1

Note

1

For further information please contact

1

Notes

* Normalized EBITDA is excluding CSR, ESOP and expenses such as consumption, manpower, other administrative costs incurred due to ongoing implementation of newly won projects aggregating Rs 2.66 Crs. wherein revenue is not proportionate to these expenses ** Normalised EBIT is excluding above mentioned expenses and including Other Income. Normalized PAT is excluding above mentioned expenses. Financial results of the Company are best monitored on an annualized basis due to the seasonal nature of our business and ongoing expansion activities as a result of which specific quarter performance may be impacted by specific events in that quarter 3 Krsnaa Diagnostics Operations- At a Glance Krsnaa Diagnostics Q1 FY24 Operations- At a Glance 1,372 Tele-reporting Centres 134 CT/MRI Centres 105 Pathology Processing Lab 1,336 Pathology Collection Centres 240+ Doctors 2,947 Total Centres and Labs 125+ District Locations 17+ States & Union Territory 31 Mn+ Patients Served Last 5 Years 10 Mn+ Patients

Notes

1 Normalized EBITDA is excluding CSR, ESOP and expenses such as consumption, manpower, other administrative costs incurred due to ongoing implementation of newly won projects aggregating Rs 2.66 Crs. wherein revenue is not proportionate to these expenses 2 Normalized PAT is excluding above mentioned expenses. Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Financial results of the Company are best monitored on an annualized basis due to the seasonal nature of our business and ongoing expansion activities as a result of which specific quarter performance may be impacted by specific events in that quarter 5 Quarterly Financial Performance Quarterly Financial Performance (Rs. Million) Core Business Covid-19 Business Revenue from Operations Other Income Total Income EBITDA1 Margin % EBIT1 Margin % Profit After Tax Margin % Reported Diluted EPS Normalized EBITDA2 Margin % Normalized EBIT2 Margin % Normalized Profit After Tax2 Margin % Q1FY24 Q1FY23 Y-o-Y Growth Q4FY23 Q-o-Q Growth 1,396 - 1

Notes

1. EBITDA is excluding CSR & ESOP. EBIT is including Other Income 2 Normalized EBITDA is excluding CSR, ESOP and expenses such as consumption, manpower, other administrative costs incurred due to ongoing implementation of newly won projects aggregating Rs 2.66 Crs. wherein revenue is not proportionate to these expenses. Normalised EBIT is excluding above mentioned expenses and including Other Income. Normalized PAT is excluding above mentioned expenses. Financial results of the Company are best monitored on an annualized basis due to the seasonal nature of our business and ongoing expansion activities as a result of which specific quarter performance may be impacted by specific events in that quarter 6 Management Perspectives Management Perspectives Commenting on the business, Ms. Pallavi Bhatevara, Managing Director, said: “Addressing the initial challenges encountered in the new fiscal year, I am pleased to share a positive turn of events. The esteemed High Court of Rajasthan has rul

Healthcare Services Distribution

• Government-provided healthcare services hold varying prominence across different regions of India. • The Northeast region boasts the highest reliance on government services, accounting for nearly 80% • The Eastern part of the country follows with a significant share of approximately 60% • Northern states contribute around 40% to • government healthcare services In contrast, the Southern and Western regions have the lowest dependence on government services, approximately 30% • On an average, government healthcare services constitute around 40% of the healthcare sector in India Payor Mix India Government Schemes 38% Insurance 51% Indian Diagnostic Industry

Indian Diagnostic Industry Growth

• The Indian Diagnostic Industry has displayed 1,360 substantial growth, witnessing a CAGR of 14% Paid out of Pocket 12% Source – Industry 472 377 240 684 710 596 FY12 FY15 FY17 FY18 FY20 FY21 INR Billion FY26E Source – Industry • Notably, the industry's value escalated from Rs. 240 billion in FY12 to Rs. 710 billion in FY21 • This impressive growth trajectory is projected to continue, with an expected expansion from Rs. 710 billion in FY21 to Rs. 1,360 billion in FY26, maintaining a steady 14% CAGR • These key points highlight the regional distribution of healthcare services and the remarkable growth trajectory of the Indian Diagnostic Industry, underlining the promising trends within the healthcare sector in India 9 Diagnostic Industry Indian Diagnostic Industry Driver Growth in noncommunicable disease (NCDs) and chronic diseases: Shift in disease profile, thus changing the level of interaction between doctors and patients from episodic to rhythmic Ageing population: India’s populati

Notes

1. 2. Maturity is on the basis of the project start date 3. Return on Capital Employed calculated as (EBIT including Other Income / Gross Block) 22 B2C Pathology Strategy for FY2024 B2C Pathology Strategy for FY2024 Expanding test menus by adding more specialized tests at disruptive prices Core strategy is to set up and operationalize Home Collection Hub and Preventive Health check up promotion in Two Phases Molecular Diagnostics Flow Cytometry Histopathology & IHC Markers Genetics (NGS) Digital Pathology & AI Specialised Test 4 Growth Strategy Phase I – Maharashtra, Punjab Phase II – Odisha, Assam, Rajasthan Map of India is not to scale and for representation purposes only 23 Best-in-class infrastructure and services at disruptive rates – high brand recall leading to increased foot-falls Best-in-class infrastructure and services at disruptive rates – high brand recall leading to increased foot-falls High quality infrastructure and services at disruptive prices creates market awareness